• Policy
• The price of Zerbaxa is listed at 60,098 won
• by Kim, Jung-Ju Oct 4, 2022 06:07am

• Company
• Industry requests re-revision of the PE exemption standards
• by Eo, Yun-Ho Sep 30, 2022 05:54am

• Policy
• Strengthen the guarantee of 21 new drug by the third quarter
• by Kim, Jung-Ju Sep 30, 2022 05:53am

• Policy
• Reevaluation deadline for listed drugs extended 5 months...
• by Kim, Jung-Ju Sep 30, 2022 05:53am

• Company
• development of Korea-Japan, the efficacy of COVID-19 drugs
• by Kim, Jin-Gu Sep 30, 2022 05:53am

• Policy
• Research service for re-evaluation of listed drug benefits
• by Lee, Tak-Sun Sep 30, 2022 05:53am

• Company
• 1st KRAS drug Lumakras can be prescribed at general hospital
• by Eo, Yun-Ho Sep 29, 2022 05:50am

• Policy
• Withdrawal of Hanmi's Olita permit, cancellation of benefit
• by Lee, Tak-Sun Sep 29, 2022 05:50am

• Company
• Ildong applies to change trial protocol after completion
• by Kim, Jin-Gu Sep 29, 2022 05:50am

• Company
• FDA approved Celltrion's anticancer drug Avastin biosimilar
• by Chon, Seung-Hyun Sep 29, 2022 05:50am